Appendix 3.
Placebo Test: The Effect of Medicare Advantage Payment Rates on Ambulatory Care Sensitive and Elective Hospitalization Rates in Markets with Low Levels of Medicare Advantage Penetration
| Acute ACS | Chronic ACS | Elective | |
|---|---|---|---|
| ln(MA Payment Rate) | 3.51 (4.4) | −2.9 (6.6) | −4.06 (4.8) |
| Black | −72.9 (71.7) | −34.6 (56.4) | −41.4 (33.6) |
| Hispanic | −1.2 (159.9) | 34.0 (189.4) | −205.3 (165.7) |
| Other Race | 22.3 (144.3) | 162.0 (236.4) | 19.7 (81.3) |
| Female | 114.7 (90.4) | 10.0 (122.0) | −42.8 (82.6) |
| Medicaid | 85.05** (38.8) | −6.5 (44.8) | 12.5 (37.0) |
| End-Stage Renal Disease | 348.3 (337.6) | 557.8 (450.1) | 240.0 (194.1) |
| Age 75 – 85 | 29.0 (43.0) | 42.4 (54.7) | 51.5 (40.5) |
| Age 85+ | 94.23* (53.1) | 133.3 (93.1) | −45.4 (79.6) |
|
| |||
| Observations | 453 | 453 | 453 |
| F-Statistic | 8.55 | 26.5 | 35.4 |
Robust standard errors in parentheses.
*
statistically significant at 10%,
**
5%,
***
1%.
452 county-year observations from 79 counties in Arizona, Florida and New York, 1999 – 2005 with less than 3% MA penetration. Medicare Advantage payments expressed as the natural logarithm of the monthly per-enrollee payment rate set at the county level ($2005).